[Skip to Content]
[Skip to Content Landing]
July 2015

Efficacy of Rapamycin in Tuberous Sclerosis–Associated Hypopigmented MaculesBack to the Future

Author Affiliations
  • 1Department of Dermatology, Atlanta Veterans Administration Medical Center, Atlanta, Georgia
  • 2Department of Dermatology, Emory University School of Medicine, Atlanta, Georgia
  • 3Winship Cancer Institute, Atlanta, Georgia
JAMA Dermatol. 2015;151(7):703-704. doi:10.1001/jamadermatol.2014.4299

The study by Wataya-Kaneda et al1 in this issue of JAMA Dermatology examines the response of hypopigmented macules in tuberous sclerosis (TS) to topical rapamycin. The authors found that topical rapamycin, 0.2%, gel led to substantial improvement of hypopigmented macules without systemic absorption and that the improvement was more marked in sun-exposed skin. This improvement was reflected in the normalization of melanosome abnormalities in treated skin. Finally, the authors note that knockdown of tuberin (tsc2) caused abnormalities in melanosome numbers compared with controls.

First Page Preview View Large
First page PDF preview
First page PDF preview